{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T19:07:20Z","timestamp":1773256040156,"version":"3.50.1"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100012151","name":"Sanming Project of Medicine in Shenzhen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012151","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1016\/j.intimp.2021.107731","type":"journal-article","created":{"date-parts":[[2021,5,6]],"date-time":"2021-05-06T20:56:23Z","timestamp":1620334583000},"page":"107731","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["Chimeric antigen receptor T cells targeting CD7 in a child with high-risk T-cell acute lymphoblastic leukemia"],"prefix":"10.1016","volume":"96","author":[{"given":"Lichun","family":"Xie","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lian","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sixi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"LungJi","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5559-633X","authenticated-orcid":false,"given":"Feiqiu","family":"Wen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2021.107731_b0005","unstructured":"A.M. Noone, N. Howlader, M. Krapcho, D. Miller, A. Brest, M. Yu, J. Ruhl, Z. Tatalovich, A. Mariotto, D.R. Lewis, H.S. Chen, E.J. Feuer, K.A. Cronin, SEER Cancer Statistics Review, 1975\u20132015. National Cancer Institute https:\/\/seer. cancer.gov\/csr\/1975_2015\/."},{"key":"10.1016\/j.intimp.2021.107731_b0010","doi-asserted-by":"crossref","first-page":"e142","DOI":"10.1016\/S1470-2045(19)30031-2","article-title":"Comparative features and outcomes between pediatric T-cell and B-cell acute lymphoblastic leukaemia","volume":"20","author":"Teachey","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.intimp.2021.107731_b0015","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1182\/blood.2019001557","article-title":"How I treat newly diagnosed T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma in children","volume":"135","author":"David","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.intimp.2021.107731_b0020","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/leu.2016.234","article-title":"Clinical impact of minimal residual disease in children with different subtypes of acute lymphoblastic leukemia treated with response-adapted therapy","volume":"31","author":"Pui","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.intimp.2021.107731_b0025","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1056\/NEJMoa1110169","article-title":"Outcomes after induction failure in childhood acute lymphoblastic leukemia","volume":"366","author":"Schrappe","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2021.107731_b0030","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/petr.12732","article-title":"Impact of pretransplant minimal residual disease on the post-transplant outcome of pediatric acute lymphoblastic leukemia","volume":"20","author":"Umeda","year":"2016","journal-title":"Pediatr. Transplant."},{"key":"10.1016\/j.intimp.2021.107731_b0035","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1111\/bjh.12639","article-title":"Minimal residual disease before and after transplantation for childhood acute lymphoblastic leukaemia: is there any room for intervention?","volume":"164","author":"Balduzzi","year":"2014","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.intimp.2021.107731_b0040","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1111\/bjh.15086","article-title":"Pre- and post-transplant minimal residual disease predicts relapse occurrence in children with acute lymphoblastic leukaemia","volume":"180","author":"Lovisa","year":"2018","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.intimp.2021.107731_b0045","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2021.107731_b0050","doi-asserted-by":"crossref","first-page":"djv439","DOI":"10.1093\/jnci\/djv439","article-title":"Chimeric antigen receptors modified T- cells for cancer therapy","volume":"108","author":"Dai","year":"2016","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.intimp.2021.107731_b0055","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41591-019-0421-7","article-title":"A safe and potent anti-CD19 CAR T cell therapy","volume":"25","author":"Ying","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.intimp.2021.107731_b0060","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1182\/blood-2017-01-761320","article-title":"CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies","volume":"130","author":"Gomes-Silva","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.intimp.2021.107731_b0065","first-page":"64","article-title":"A novel CD7 chimeric antigen receptor-modified NK-92MI cell line targeting T-cell acute lymphoblastic leukemia","volume":"9","author":"You","year":"2019","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.intimp.2021.107731_b0070","doi-asserted-by":"crossref","unstructured":"J.P. Zhang, R. Zhang, S.T. Tsao, Y.C. Liu, X. Chen, D.P. Lu, P. Castillo, L.J. Chang, Sequential allogeneic and autologous CAR-T-cell therapy to treat an immune-compromised leukemic patient. Blood Adv. 2 (2018) 1691\u20131695. https:\/\/dx.doi.org\/10.1182%2Fbloodadvances.2018017004.","DOI":"10.1182\/bloodadvances.2018017004"},{"key":"10.1016\/j.intimp.2021.107731_b0075","first-page":"674","article-title":"GD2 chimeric antigen receptor modified T cells in synergy with sub-toxic level of doxorubicin targeting osteosarcomas","volume":"10","author":"Chulanetra","year":"2020","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.intimp.2021.107731_b0080","doi-asserted-by":"crossref","first-page":"685","DOI":"10.3389\/fonc.2020.00685","article-title":"Successful anti-CLL1 CAR T-cell therapy in secondary acute myeloid leukemia","volume":"10","author":"Zhang","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.intimp.2021.107731_b0085","doi-asserted-by":"crossref","first-page":"40","DOI":"10.2174\/1566523218666181116093857","article-title":"Functional improvement of chimeric antigen receptor through intrinsic interleukin-15R\u03b1 signaling","volume":"19","author":"Nair","year":"2019","journal-title":"Curr. Gene Ther."},{"key":"10.1016\/j.intimp.2021.107731_b0090","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41571-018-0075-2","article-title":"Pediatric Acute Lung Injury and Sepsis Investigators (PALISI) Network, Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy","volume":"16","author":"Mahadeo","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.intimp.2021.107731_b0095","doi-asserted-by":"crossref","unstructured":"C. Jiang, W. Zhao, M. Qin, M. Jin, L.-J. Chang, X. Ma, CD56-chimeric antigen receptor T-cell therapy for refractory\/recurrent rhabdomyosarcoma, Medicine 10 (2019) 98, 43.","DOI":"10.1097\/MD.0000000000017572"},{"issue":"5","key":"10.1016\/j.intimp.2021.107731_b0100","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1158\/1078-0432.CCR-20-1271","article-title":"Eradication of T-ALL Cells by CD7-targeted Universal CAR-T Cells and Initial Test of Ruxolitinib-based CRS Management","volume":"27","author":"Li","year":"2021","journal-title":"Clin Cancer Res."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576921003672?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576921003672?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,25]],"date-time":"2024-09-25T19:06:19Z","timestamp":1727291179000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576921003672"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":20,"alternative-id":["S1567576921003672"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2021.107731","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chimeric antigen receptor T cells targeting CD7 in a child with high-risk T-cell acute lymphoblastic leukemia","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2021.107731","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"107731"}}